Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 7/20 | 0.54 |
| ▸ | HTR3A | P46098 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | HTR6 | P50406 | 7/20 | 0.51 |
| ▸ | DRD2 | P14416 | 6/20 | 0.51 |
| ▸ | HTR7 | P34969 | 6/20 | 0.51 |
| ▸ | HTR2A | P28223 | 5/20 | 0.51 |
| ▸ | KCNK2 | O95069 | 1/20 | 0.49 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.49 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7278805 | 0.89 | KCNK2 (0.53) | HRH4HTR3AKMT2AHTR6DRD2 | |
| SCHEMBL7273434 | 0.85 | PIK3CA (0.48) | KMT2A | |
| SCHEMBL134764 | 0.82 | KCNK2 (0.67) | HRH4HTR3AKMT2AHTR6DRD2 | |
| SCHEMBL7273354 | 0.82 | HRH4 (0.50) | HRH4HTR3AKMT2AHTR6DRD2 | |
| SCHEMBL7278942 | 0.80 | HTR6 (0.48) | HRH4HTR3AKMT2AHTR6DRD2 | |
| SCHEMBL7165985 | 0.78 | HRH4 (0.50) | HRH4HTR3AKMT2AHTR6HRH3 | |
| SCHEMBL7272345 | 0.77 | KCNK2 (0.71) | HRH4HTR3AKMT2AHTR6DRD2 | |
| SCHEMBL6049569 | 0.72 | DHFR (0.46) | KMT2AHTR2A | |
| SCHEMBL26037956 | 0.71 | HRH4 (0.61) | HRH4HTR3AKMT2A | |
| SCHEMBL604257 | 0.70 | HRH4 (1.00) | HRH4HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5712276-A | TREATING NERVOUS SYSTEM DISORDERS | GLAXO WELLCOME INC. (US) | 1998-01-27 | — | — | US | claimed |
| US-5684005-A | PHENYLPYRIMIDINE COMPOUNDS AS INHIBITORS OF EXCITATORY AMINO ACID GLUTAMATE | GLAXO WELLCOME INC. (US) | 1997-11-04 | — | — | US | claimed |
| EP-0727213-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-21 | — | — | EP | claimed |
| EP-0372934-A2 | Pharmacologically active CNS compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-06-13 | — | — | EP | claimed |
| EP-1681058-A2 | Pharmacologically active cns compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 2006-07-19 | — | — | EP | disclosed |
| EP-1325916-A1 | Piperazinyl-substituted phenyl pyrimidine derivatives useful in the treatment or prevention of disorders of the central nervous system | THE WELLCOME FOUNDATION LIMITED (GB) | 2003-07-09 | — | — | EP | disclosed |
| CN-1066719-C | Process for preparing compounds having pharmacological activity on the central nervous system | WELLCOME FOUND (GB) | 2001-06-06 | — | — | CN | disclosed |
| US-5712276-A | TREATING NERVOUS SYSTEM DISORDERS | GLAXO WELLCOME INC. (US) | 1998-01-27 | — | — | US | disclosed |
| US-5684005-A | PHENYLPYRIMIDINE COMPOUNDS AS INHIBITORS OF EXCITATORY AMINO ACID GLUTAMATE | GLAXO WELLCOME INC. (US) | 1997-11-04 | — | — | US | disclosed |
| US-5635507-A | PIPERAZINYL PHENYLPYRIMIDINE COMPOUND TREATING BRAIN DISORDER | GLAXO WELLCOME INC. (US) | 1997-06-03 | — | — | US | disclosed |
| US-5597828-A | TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS SUCH AS CEREBRAL ISCHEMIC DAMAGE AND EPILEPSY | GLAXO WELLCOME INC. (US) | 1997-01-28 | — | — | US | disclosed |
| US-5597827-A | CENTRAL NERVOUS SYSTEM DISORDERS AND ANTIISCHEMIC AGENTS | GLAXO WELLCOME INC. | 1997-01-28 | — | — | US | disclosed |
| EP-0727214-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-21 | — | — | EP | disclosed |
| EP-0727213-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-08-21 | — | — | EP | disclosed |
| EP-0715851-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment of prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-06-12 | — | — | EP | disclosed |
| EP-0713703-A2 | Substituted phenylpyrimidine derivatives, useful in the treatment or prevention of CNS disorders | THE WELLCOME FOUNDATION LIMITED (GB) | 1996-05-29 | — | — | EP | disclosed |
| CN-1117046-A | Method for preparing pharmaceutically active CNS compounds | WELLCOME FOUND (GB) | 1996-02-21 | — | — | CN | disclosed |
| US-5136080-A | Intermediates for glutamate inhibitors | BURROUGHS WELLCOME CO. (US) | 1992-08-04 | — | — | US | disclosed |
| CN-1052306-A | Compounds having pharmacological activity on the central nervous system | WELLCOME FOUND (GB) | 1991-06-19 | — | — | CN | disclosed |
| EP-0372934-A2 | Pharmacologically active CNS compounds | THE WELLCOME FOUNDATION LIMITED (GB) | 1990-06-13 | — | — | EP | disclosed |